MangoRx to Introduce “MOJO” Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate and Pregnenolone for Treatment of Low Testosterone and Male Hormone Imbalances

Rhea-AI Summary

MangoRx has announced the upcoming release of MOJO, a new oral dissolvable tablet aimed at treating low testosterone and male hormone imbalances. The product will combine Enclomiphene Citrate, Pregnenolone, and DHEA, and will be marketed to younger males as a $199 monthly subscription. MOJO is designed to stimulate natural testosterone production and support overall hormonal balance, offering a complementary alternative to MangoRx's existing PRIME Testosterone Replacement Therapy. The launch is scheduled before the end of Q2 2024, with the company aiming to capture a significant share of the growing testosterone replacement therapy market, projected to reach $2.9 billion by 2032.

Positive

• MangoRx is launching MOJO, a new product for low testosterone and male hormone imbalances.
• MOJO combines Enclomiphene Citrate, Pregnenolone, and DHEA, known for boosting natural testosterone production.
• MOJO will be sold on a subscription basis at $199 per month.
• The product targets younger males and offers an alternative to traditional testosterone replacement therapies.
• The testosterone replacement therapy market is projected to reach $2.9 billion by 2032.
• MangoRx utilizes a telemedicine platform for convenient prescription and delivery services.
• MOJO is positioned to capture a significant market share in the male hormone therapy sector.

Negative

• The price of $199 per month for MOJO might be considered high for some consumers.
• The product is yet to be launched and its market acceptance remains uncertain.
• There is no mention of FDA approval for MOJO, unlike the existing PRIME therapy.
• Potential side effects and long-term efficacy of MOJO are not detailed in the announcement.
• The success of MOJO relies on the effectiveness of its marketing and consumer adoption.

Insights

Medical Research Analyst

MOJO represents an interesting advancement in the field of male hormonal therapies. The combination of Enclomiphene Citrate, DHEA and Pregnenolone is particularly noteworthy given their distinct roles in hormone regulation. Enclomiphene Citrate, a purified isomer of Clomid, stimulates the body's natural testosterone production, which is a significant benefit over traditional testosterone replacement therapies (TRTs) that can suppress endogenous hormone production and fertility.

Pregnenolone and DHEA are precursors to several important hormones and can have a broad impact on overall hormone balance, mood and cognitive function. The inclusion of these compounds may offer a more holistic approach to treating low testosterone levels, potentially addressing some of the side effects seen with other treatments. However, long-term efficacy and safety data for this particular combination in an ODT format will be critical for its acceptance among medical professionals.

Market Research Analyst

The market for testosterone replacement therapy is substantial, with projections reaching $2.9 billion by 2032. MOJO's positioning as a subscription-based product targeting a younger demographic is a smart strategic move. Younger men experiencing early stages of low testosterone might prefer a solution that supports natural hormone production. By offering an oral dissolvable tablet (ODT), MangoRx is addressing convenience, which could enhance adherence and overall success rates.

However, competition in this space is fierce and MangoRx will need to differentiate MOJO effectively. The pricing at $199 per month may be a barrier for some, particularly when compared to other therapies. The effectiveness of their marketing and the perceived value of MOJO will be important in capturing a significant market share.

MOJO to be offered as an Oral Dissolvable Tablet (ODT) marketed to younger male demographic as an alternative to PRIME Testosterone Replacement Therapy (TRT)

Dallas, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss and hormone replacement therapies, is pleased to announce the development of proprietary formulations of Enclomiphene Citrate, Pregnenolone and Dehydroepiandrosterone (DHEA) in an Oral Dissolvable Tablet (ODT) aimed at restoring hormonal balance and naturally increasing testosterone levels in men. The new compounded product will be named “MOJO” and sold exclusively on MangoRx’s website on a subscription basis at a price of $199 per month.

MOJO represents the groundbreaking advancement in addressing male hormonal imbalances, particularly hypogonadism (low testosterone) through this unique and powerful formulation and will be offered as an alternative to the Company’s existing FDA approved oral Testosterone Replacement Therapy (TRT), PRIME by MangoRx, powered by Kyzatrex^®.

MOJO’s key components and therapeutic benefits include the following innovative compounded ingredients:

• Enclomiphene Citrate: A purified isomer of Clomid (Clomiphene Citrate) which has been FDA approved since 1967 and has been proven to be effective in stimulating the body's natural testosterone production, addressing hormonal imbalances at their source.
• DHEA: A precursor hormone that supports overall hormonal balance, DHEA is linked to improvements in energy levels, mood, and general well-being.
• Pregnenolone: Known as the “mother hormone,” Pregnenolone plays a crucial part in the production of other essential hormones and supports cognitive and mental health.
  

"Our new Enclomiphene citrate formulation, MOJO, represents a significant breakthrough in the treatment of male hormonal imbalances," said Jacob Cohen, Co-Founder and CEO of MangoRx. "With our most recent launch of PRIME by MangoRx, powered by Kyzatrex®, MOJO is intended to be complementary to PRIME and marketed to those in the earlier stages of experiencing secondary hypogonadism, or low testosterone. This product underscores our commitment to advancing the standard of care in male hormonal therapy and improving the lives of our patients."

Low testosterone is a widespread condition that affects millions of men globally, presenting significant challenges to overall health and quality of life. Traditional treatments often present undesirable side effects or compromise fertility. MOJO leverages and features the synergistic effects of Enclomiphene citrate, DHEA, and Pregnenolone to address these issues effectively and safely, setting a new standard in male hormonal therapy.

The market for treatments addressing male hormonal imbalances is substantial and growing. In the United States alone, millions of men suffer from hypogonadism, with the global market for testosterone replacement therapy projected to reach $2.9 billion by 2032 according to Allied Market Research. MangoRx’s new formulation, MOJO, which is anticipated to be launched on the Company’s website before the end of the 2^nd quarter, is well-positioned to capture a significant share of this market, offering a superior alternative to traditional therapies.

About MangoRx

MangoRx is focused on developing a variety of men's health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men's wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth and hormone replacement therapies. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com or on social media @Mango.Rx.

Cautionary Note Regarding Forward-Looking Statements

Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). These forward-looking statements represent the Company’s current expectations or beliefs concerning future events and can generally be identified using statements that include words such as “estimate,” “expects,” “project,” “believe,” “anticipate,” “intend,” “plan,” “foresee,” “forecast,” “likely,” “will,” “target” or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company’s control which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, our ability to meet Nasdaq’s minimum bid price requirement; the Company’s stockholders’ equity as of the Company’s next fiscal quarter end; our ability to maintain the listing of our common stock on Nasdaq; our ability to commercialize our patent portfolio; our ability to obtain Comisión Federal para la Protección contra Riesgos Sanitarios for our ED product in Mexico, the costs thereof and timing associated therewith; our ability to obtain additional funding and generate revenues to support our operations; risks associated with our ED product which have not been, and will not be, approved by the U.S. Food and Drug Administration (“FDA”) and have not had the benefit of the FDA’s clinical trial protocol which seeks to prevent the possibility of serious patient injury and death; risks that the FDA may determine that the compounding of our planned products does not fall within the exemption from the Federal Food, Drug, and Cosmetic Act (“FFDCA Act”) provided by Section 503A; risks associated with related party relationships and agreements; the effect of data security breaches, malicious code and/or hackers; competition and our ability to create a well-known brand name; changes in consumer tastes and preferences; material changes and/or terminations of our relationships with key parties; significant product returns from customers, product liability, recalls and litigation associated with tainted products or products found to cause health issues; our ability to innovate, expand our offerings and compete against competitors which may have greater resources; our significant reliance on related party transactions; the projected size of the potential market for our technologies and products; risks related to the fact that our Chairman and Chief Executive Officer, Jacob D. Cohen has significant voting control over the Company; risks related to the significant number of shares in the public float, our share volume, the effect of sales of a significant number of shares in the marketplace, and the fact that the majority of our shareholders paid less for their shares than the public offering price of our common stock in our recent initial public offering; dilution caused by recent offerings; conversion of outstanding shares of preferred stock and the rights and preferences thereof, the fact that we have a significant number of outstanding warrants to purchase shares of common stock at $1.00 per share, the resale of which underlying shares have been registered under the Securities Act of 1933, as amended; our ability to build and maintain our brand; cybersecurity, information systems and fraud risks and problems with our websites; changes in, and our compliance with, rules and regulations affecting our operations, sales, marketing and/or our products; shipping, production or manufacturing delays; regulations we are required to comply with in connection with our operations, manufacturing, labeling and shipping; our dependency on third-parties to prescribe and compound our ED product; our ability to establish or maintain relations and/or relationships with third-parties; potential safety risks associated with our Mango ED product, including the use of ingredients, combination of such ingredients and the dosages thereof; the effects of changing rates of inflation and interest rates, and economic downturns, including potential recessions, as well as macroeconomic, geopolitical, health and industry trends, pandemics, acts of war (including the ongoing Ukraine/Russian conflict and war in Israel) and other large-scale crises; our ability to protect intellectual property rights; our ability to attract and retain key personnel to manage our business effectively; overhang which may reduce the value of our common stock; volatility in the trading price of our common stock; and general consumer sentiment and economic conditions that may affect levels of discretionary customer purchases of the Company’s products, including potential recessions and global economic slowdowns. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements we make in this release are reasonable, we provide no assurance that these plans, intentions or expectations will be achieved. Consequently, you should not consider any such list to be a complete set of all potential risks and uncertainties.

More information on potential factors that could affect the Company’s financial results is included from time to time in the “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and our Quarterly Report on Form 10-Q for the three months ended March 31, 2024. These filings are available at www.sec.gov and at our website at https://www.mangoceuticals.com/sec-filings. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Follow Mangoceuticals and MangoRx on social media:
https://www.instagram.com/mango.rx
https://twitter.com/Mangoceuticals
https://www.facebook.com/MangoRxOfficial

FOR INVESTOR RELATIONS
Mangoceuticals Investor Relations
Email: investors@mangorx.com

SOURCE: Mangoceuticals Inc.

FAQ

What is MOJO by MangoRx?

MOJO is a new oral dissolvable tablet by MangoRx designed to treat low testosterone and male hormone imbalances.

What are the key ingredients in MOJO by MangoRx?

MOJO contains Enclomiphene Citrate, Pregnenolone, and DHEA.

How much does MOJO by MangoRx cost?

MOJO is priced at $199 per month on a subscription basis.

When will MOJO by MangoRx be available?

MOJO is expected to be available before the end of Q2 2024.

How is MOJO by MangoRx different from other testosterone therapies?

MOJO is marketed as an alternative to traditional therapies, focusing on natural testosterone production and overall hormonal balance.

Is MOJO by MangoRx FDA approved?

The press release does not mention FDA approval for MOJO.